<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="20" offset="0" totalResults="24264"><SearchResults><Drug id="75799" name="autologous NY-ESO-1-targeting dendritic cell vaccine (cancer), Roswell Park Comprehensive Cancer Center" lastModificationDate="2018-06-11T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Roswell Park Comprehensive Cancer Center</CompanyOriginator><CompaniesPrimary><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesPrimary><IndicationsPrimary><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>triad of costimulatory molecules (B7-1, ICAM-1 and LFA-3), for the potential sc treatment of &lt;b&gt;cancer&lt;/b&gt;, including ovarian, peritoneal and fallopian tube &lt;b&gt;cancer&lt;/b&gt; [ 2042231 ], [ 1267438 ], [...1257708 ], [ 1267440 ], [ 1267443 ], [ 2042231 ]. By February 2004, a clinical trial was underway in patients with ovarian &lt;b&gt;cancer&lt;/b&gt;. In June 2011, a phase I trial was completed [ 1267439 ]. By June 2014, another phase I trial was ongoing [ 1267438 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2012-01-27T00:00:00Z</AddedDate></Drug><Drug id="45057" name="NY-ESO-1 vaccine (protein), Ludwig Institute" lastModificationDate="2018-07-09T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Ludwig Institute for Cancer Research</CompanyOriginator><CompaniesPrimary><Company>Ludwig Institute for Cancer Research</Company></CompaniesPrimary><IndicationsPrimary><Indication>Melanoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Tumor antigen</Technology></Technologies><Summary>The Ludwig Institute for &lt;b&gt;Cancer&lt;/b&gt; Research (LICR) is developing a therapeutic vaccine based on the tumor antigen NY-ESO-1 using CSL 's ISCOM technology for the potential treatment for &lt;b&gt;cancer&lt;/b&gt;, primarily melanoma [ 455844 ]. In May 2014, a phase II data were presented [ 1560467 ]. In April 2013, a phase I trial was initiated in the US in patients with metastatic melanoma. At that time, the trial was expected to complete in May 2016. In October 2015, the trial was ongoing [ 1713389 ].</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2003-05-21T00:00:00Z</AddedDate></Drug><Drug id="45079" name="NY-ESO-1 vaccine (peptides), Ludwig Institute/Peking University/Jewim Pharmaceutical" lastModificationDate="2019-05-30T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Ludwig Institute for Cancer Research</CompanyOriginator><CompaniesPrimary><Company>Ludwig Institute for Cancer Research</Company></CompaniesPrimary><IndicationsPrimary><Indication>Melanoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><Summary>for &lt;b&gt;Cancer&lt;/b&gt; Research (LICR) is developing vaccines, based on peptides of the tumor antigen NY-ESO-1 that elicit a cytotoxic T-cell response, for the potential treatment of &lt;b&gt;cancer&lt;/b&gt; [ 490400 ]. In January 2015, a phase II trial for melanoma...Research, were developing NY-ESO-1b peptide vaccine in China, for the potential treatment of liver &lt;b&gt;cancer&lt;/b&gt;. In December 2008, the drug was in phase I trial [ 1468241 ], [ 1468242 ], [ 1468244 ], [ 1468247 ]. In October 2014, it was under development</Summary><CompaniesSecondary><Company>Jewim Pharmaceutical Inc</Company><Company>Peking University</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication><Indication>Liver tumor</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2003-05-22T00:00:00Z</AddedDate></Drug><Drug id="45059" name="NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed" lastModificationDate="2017-02-13T00:00:00Z" phaseHighest="Discontinued"><CompanyOriginator>Ludwig Institute for Cancer Research</CompanyOriginator><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal high velocity particle formulation</Technology></Technologies><Summary>the potential treatment of &lt;b&gt;cancer&lt;/b&gt; [ 539274 ], [ 762237 ]. In September 2004, phase I trials were initiated [ 559440 ]; these were ongoing in January 2007 [ 762237 ]. However, since that date no further development...time, PowderMed expected the vaccine to enter clinical trials for lung &lt;b&gt;cancer&lt;/b&gt; within 2 years [ 539274 ]. LICR is also developing an NY-ESO-1 protein vaccine with CSL ,and an NY-ESO-1 pox-virus &lt;b&gt;cancer&lt;/b&gt; vaccine with Therion .</Summary><CompaniesSecondary><Company>Ludwig Institute for Cancer Research</Company><Company>PowderJect Pharmaceuticals plc</Company><Company>PowderMed Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2003-05-21T00:00:00Z</AddedDate></Drug><Drug id="55922" name="SCIB-2" lastModificationDate="2019-05-30T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Scancell Ltd</CompanyOriginator><CompaniesPrimary><Company>Cancer Research UK</Company><Company>Scancell Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Non-small-cell lung cancer</Indication><Indication>Solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Liposome formulation</Technology><Technology>Nanoparticle formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein fusion</Technology></Technologies><Summary>lung &lt;b&gt;cancer&lt;/b&gt; (NSCLC), lung &lt;b&gt;cancer&lt;/b&gt;, oesophageal, prostate and other epithelial cancers [ 683874 ], [ 942804 ], [ 1204618 ], [ 1601884 ], [ 1644219 ], [ 1991498...expected that the development of the work would be undertaken by a licensing partner [ 1331002 ]; in December 2017, &lt;b&gt;Cancer&lt;/b&gt; Research UK agreed to conduct a UK-based phase I/II clinical trial of SCIB-2 in combination with a checkpoint inhibitor</Summary><ActionsSecondary><Action>Anticancer</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action><Action>Vascular damaging agent</Action></ActionsSecondary><AddedDate>2006-08-15T00:00:00Z</AddedDate></Drug><Drug id="24064" name="rV-NY-ESO-1/rF-NY-ESO-1 prime-boost breast cancer vaccine, Ludwig Institute/Therion" lastModificationDate="2017-08-07T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Ludwig Institute for Cancer Research (US)</CompanyOriginator><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>for &lt;b&gt;Cancer&lt;/b&gt; Research (LICR) and Therion Biologics were developing a pox virus vector vaccine expressing the NY-ESO-1 tumor-associated antigen for the potential treatment of breast &lt;b&gt;cancer&lt;/b&gt; [ 387199 ], [ 434718 ]. The vaccine was being developed...carried out by LICR were released in 2003 [ 491601 ], [ 515317 ]. In early 2004, investigator-led phase I trials in breast &lt;b&gt;cancer&lt;/b&gt; were ongoing [ 528184 ]; at that time, Therion had not yet taken the vaccine into its own internal pipeline [ 528184 ], [ 529517</Summary><CompaniesSecondary><Company>Ludwig Institute for Cancer Research (US)</Company><Company>Sanofi Pasteur</Company><Company>Therion Biologics Corp</Company></CompaniesSecondary><IndicationsSecondary><Indication>Breast tumor</Indication><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>1999-06-25T00:00:00Z</AddedDate></Drug><Drug id="100554" name="T-cell receptor mimic mABs (cancer), Xencor" lastModificationDate="2019-05-30T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Xencor Inc</CompanyOriginator><CompaniesPrimary><Company>Xencor Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody</Technology></Technologies><Summary>Xencor is investigating T-Cell Receptor Mimic (TCRm) monoclonal antibodies which target &lt;b&gt;cancer&lt;/b&gt; testis antigen NY-ESO1, for the potential treatment of &lt;b&gt;cancer&lt;/b&gt; [ 1726823 ]. The program is under license from Receptor Logic specifically to target NY-ESO1 [ 1726823 ].</Summary><CompaniesSecondary><Company>Receptor Logic Inc</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action></ActionsSecondary><AddedDate>2016-01-13T00:00:00Z</AddedDate></Drug><Drug id="112776" name="hematopoietic stem cell-derived anti-NY-ESO-1/HLA-DP4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (ovarian/fallopian tube/primary peritoneal cancer), Roswell Park Comprehensive Cancer Center" lastModificationDate="2019-01-29T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Roswell Park Comprehensive Cancer Center</CompanyOriginator><CompaniesPrimary><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesPrimary><IndicationsPrimary><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>HLA class I antigen A-2 alpha modulator</Action><Action>HLA class II antigen modulator</Action></ActionsPrimary><Technologies><Technology>Autologous stem cell therapy</Technology><Technology>Biological therapeutic</Technology><Technology>Haematopoietic stem cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><Summary>CD8 TCR specific for NY-ESO-1 in the context of HLA-A*0201, for the potential treatment of ovarian, fallopian tube and primary peritoneal &lt;b&gt;cancer&lt;/b&gt; [ 2080080 ]. In January 2019, a phase I trial in recurrent...or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; was initiated [ 2080080 ]. Roswell is also developing an anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy + dnTGFbetaRII tumor infiltrating lymphocyte therapy for the potential treatment of &lt;b&gt;cancer&lt;/b&gt;.</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2018-10-22T00:00:00Z</AddedDate></Drug><Drug id="88864" name="NY-ESO-1-specific autologous CD8+ T-cell therapy (sarcoma), Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium/National Cancer Institute" lastModificationDate="2017-11-13T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</CompanyOriginator><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Systemic formulation unspecified</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Fred Hutchinson &lt;b&gt;Cancer&lt;/b&gt; Research Center/University of Washington &lt;b&gt;Cancer&lt;/b&gt; Consortium in collaboration with National &lt;b&gt;Cancer&lt;/b&gt; Institute , was developing NY-ESO-1-specific, autologous CD8+ T-cell therapy for the potential treatment of soft tissue sarcoma including round cell liposarcoma and synovial sarcoma. In January 2012, a phase I trial began and in August 2013, the trial was ongoing [ 1504974 ]. In December</Summary><CompaniesSecondary><Company>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</Company><Company>National Cancer Institute</Company></CompaniesSecondary><IndicationsSecondary><Indication>Soft tissue sarcoma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Immunostimulant</Action></ActionsSecondary><AddedDate>2013-12-04T00:00:00Z</AddedDate></Drug><Drug id="64055" name="GSK-3377794" lastModificationDate="2018-12-05T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Adaptimmune Therapeutics plc</CompanyOriginator><CompaniesPrimary><Company>GlaxoSmithKline plc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Liposarcoma</Indication><Indication>Metastatic non small cell lung cancer</Indication><Indication>Multiple myeloma</Indication><Indication>Ovary tumor</Indication><Indication>Soft tissue sarcoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>HLA class I antigen A-2 alpha modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><Summary>of &lt;b&gt;cancer&lt;/b&gt;, including metastatic non small cell lung &lt;b&gt;cancer&lt;/b&gt; (NSCLC), multiple myeloma (MM), synovial&amp;nbsp;sarcoma...was ongoing for MM [ 2059415 ]. In June 2013, a phase I/II ovarian &lt;b&gt;cancer&lt;/b&gt; trial began [ 1277243 ]. In September 2017, following development transition to GSK, Adaptimmune...other &lt;b&gt;cancer&lt;/b&gt; indications. In March 2015, the program was in phase I/II development for esophageal &lt;b&gt;cancer&lt;/b&gt; [ 1643152 ]. However no further development for that</Summary><CompaniesSecondary><Company>Adaptimmune Therapeutics plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication><Indication>Esophagus tumor</Indication><Indication>Melanoma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2009-07-24T00:00:00Z</AddedDate></Drug><Drug id="79354" name="NY-ESO-1/LAGE-1 class I/II peptide vaccine (prostate cancer), Baylor College of Medicine/NCI" lastModificationDate="2016-09-29T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Baylor College of Medicine</CompanyOriginator><ActionsPrimary><Action>Cancer testis antigen 2 modulator</Action><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Baylor College of Medicine and the National &lt;b&gt;Cancer&lt;/b&gt; Institute were developing a peptide vaccine, based on the NY-ESO-1 and LAGE-1 class I and II peptides, for the potential sc treatment of prostate &lt;b&gt;cancer&lt;/b&gt; [ 1308254 ]. In April 2006, phase I studies began [ 1308254 ], [ 1295806 ]; in April 2012, these were ongoing [ 1295806 ], [ 1307788 ].</Summary><CompaniesSecondary><Company>Baylor College of Medicine</Company><Company>National Cancer Institute</Company></CompaniesSecondary><IndicationsSecondary><Indication>Prostate tumor</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2012-07-13T00:00:00Z</AddedDate></Drug><Drug id="99921" name="WT-1 analog peptide + NY-ESO-1 overlapping peptide vaccine (ovarian cancer), Memorial Sloan-Kettering Cancer Center" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Memorial Sloan-Kettering Cancer Center</CompanyOriginator><CompaniesPrimary><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesPrimary><IndicationsPrimary><Indication>Ovary tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Peptide</Technology></Technologies><Summary>Memorial Sloan-Kettering &lt;b&gt;Cancer&lt;/b&gt; Center is investigating a multi-antigen vaccine containing WT-1 analog peptide and NY-ESO-1 overlapping peptide, for the potential treatment of ovarian &lt;b&gt;cancer&lt;/b&gt;. In September 2015, development was underway [ 1714301 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="52705" name="IMF-001" lastModificationDate="2018-07-16T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>ImmunoFrontier Inc</CompanyOriginator><CompaniesPrimary><Company>ImmunoFrontier Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication><Indication>Esophagus tumor</Indication><Indication>Prostate tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tumor antigen</Technology></Technologies><Summary>(CHP-NY-ESO-1), based on the tumor antigen NY-ESO-1 (CTAG1) formulated in nanoparticles of cholesteryl hydrophobized pullulan, for the potential sc treatment of &lt;b&gt;cancer&lt;/b&gt; including esophageal and prostate &lt;b&gt;cancer&lt;/b&gt; [ 578795 ], [ 1056765 ], [ 1465707 ], [ 1637873 ]. In April 2012, a phase II trial was initiated in patients with esophageal &lt;b&gt;cancer&lt;/b&gt;, in Japan. In August 2013, the trial was ongoing [ 1408924 ]. In January 2017, this was still the case [ 1890822 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2005-01-24T00:00:00Z</AddedDate></Drug><Drug id="71482" name="LV-305" lastModificationDate="2018-09-27T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Immune Design Corp</CompanyOriginator><CompaniesPrimary><Company>Immune Design Corp</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Liposarcoma</Indication><Indication>Metastatic breast cancer</Indication><Indication>Metastatic non small cell lung cancer</Indication><Indication>Ovary tumor</Indication><Indication>Sarcoma</Indication><Indication>Soft tissue sarcoma</Indication><Indication>Stage IV melanoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 inhibitor</Action><Action>T-cell surface glycoprotein CD8 stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intradermal formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>NanoPass' MicronJet6000 microneedle device, for the potential treatment of &lt;b&gt;cancer&lt;/b&gt; including melanoma, ovarian &lt;b&gt;cancer&lt;/b&gt;, liposarcoma, synovial sarcoma, non-small cell lung &lt;b&gt;cancer&lt;/b&gt;, and breast &lt;b&gt;cancer&lt;/b&gt; [ 1186633 ], [ 1203575 ], [ 1239930 ], [ 1287303 ], [ 1441538 ], [ 1491818 ], [ 1611539 ], [ 1566350 ], [ 1566143 ], [ 1692476 ], [ 2042825 ], [ 2137387 ]. In April 2014, a phase I trial was initiated in advanced or metastatic &lt;b&gt;cancer&lt;/b&gt; [ 1566350 ], [ 1566143 ]. In September 2018, a phase I trial was initiated</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2011-05-23T00:00:00Z</AddedDate></Drug><Drug id="101739" name="IMM-65" lastModificationDate="2019-01-15T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>iOx Therapeutics Ltd</CompanyOriginator><CompaniesPrimary><Company>iOx Therapeutics Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Nanoparticle formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>iOx Therapeutics is investigating IMM-65, a combination of IMM-60 , an invariant natural killer T (iNKT) cell agonist, with NY-ESO-1 tumor vaccine, as a nanoparticle formulation, for the potential treatment of &lt;b&gt;cancer&lt;/b&gt; [ 1754166 ], [ 1942299 ]. In July 2015, the company had discussed plans for a first human trial with the UK Medicines and Healthcare products Regulatory Agency [ 1754494 ]. In April 2016, development was ongoing [ 1754166 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Immunostimulant</Action><Action>Natural killer T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2016-04-25T00:00:00Z</AddedDate></Drug><Drug id="67714" name="12D7" lastModificationDate="2018-04-04T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>CT Atlantic AG</CompanyOriginator><CompaniesPrimary><Company>XBiotech Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody human</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>XBiotech , under license from CT Atlantic , is investigating 12D7 (previously CTA-001, CTA001.12D7), the lead from a series of human mAbs targeting NY-ESO-1, using the CT Atlanticâ€™s B Cell Display Technology, for the potential treatment of &lt;b&gt;cancer&lt;/b&gt; [ 1124405 ], [ 1181689 ], [ 2018841 ]. In April 2018, XBiotech was planning clinical development [ 2018841 ].</Summary><CompaniesSecondary><Company>CT Atlantic AG</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action></ActionsSecondary><AddedDate>2010-08-16T00:00:00Z</AddedDate></Drug><Drug id="108747" name="anti-NY-ESO-1 TCR T-cell therapy (cancer), Shenzhen BinDeBio" lastModificationDate="2018-11-27T00:00:00Z" phaseHighest="Clinical"><CompanyOriginator>Shenzhen BinDeBio Ltd.</CompanyOriginator><CompaniesPrimary><Company>Shenzhen BinDeBio Ltd.</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>HLA antigen modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><Summary>Shenzhen BinDeBio is developing an immunotherapy comprising NY-ESO-1-specific TCR-engineered T cells for the potential iv treatment of &lt;b&gt;cancer&lt;/b&gt;, including lung &lt;b&gt;cancer&lt;/b&gt;, esophageal carcinoma and melanoma. By September 2017, a clinical trial had been initiated [ 1992007 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2017-12-21T00:00:00Z</AddedDate></Drug><Drug id="78038" name="NY-ESO-1 vaccine (MPLA-adjuvanted, cancer), Instituto Butantan" lastModificationDate="2017-08-14T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Instituto Butantan</CompanyOriginator><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><Summary>this program is assumed to be discontinued. Instituto Butantan was investigating a vaccine containing the tumor antigen NY-ESO-1, combined with the Bordetella pertussis-derived adjuvant MPLA (monophosphoryl lipid A), for the potential im treatment of &lt;b&gt;cancer&lt;/b&gt;. In April 2012, a phase I trial was planned to begin in July later that year [ 1290916 ].</Summary><CompaniesSecondary><Company>Instituto Butantan</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2012-05-16T00:00:00Z</AddedDate></Drug><Drug id="100580" name="anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy + dnTGFbetaRII tumor infiltrating lymphocytes (solid tumor), Roswell Park Comprehensive Cancer Center" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Roswell Park Comprehensive Cancer Center</CompanyOriginator><CompaniesPrimary><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesPrimary><IndicationsPrimary><Indication>Solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>HLA class I antigen A-2 alpha modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Lymphocyte</Technology><Technology>Lymphocyte cell therapy</Technology><Technology>Protein recombinant</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><Summary>Roswell Park Comprehensive &lt;b&gt;Cancer&lt;/b&gt; Center is developing a combination immunotherapy comprising autologous peripheral blood lymphocytes (PBL) retrovirally transduced with T cell receptors (TCR) specific for NY-ESO-1 in the context of HLA-A*0201...initiated; in November 2018, the trial was ongoing [ 1727315 ]. Roswell is also developing a hematopoietic stem cell-derived anti-NY-ESO-1/HLA-DP4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy for the potential treatment of &lt;b&gt;cancer&lt;/b&gt;.</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2016-01-15T00:00:00Z</AddedDate></Drug><Drug id="97991" name="NY-ESO-1 targeted self-adjuvanting peptide vaccines (cancer), SapVax" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>University of Auckland</CompanyOriginator><CompaniesPrimary><Company>SapVax LLC</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>TLR-2 agonist</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Peptide</Technology></Technologies><Summary>SapVax , a spin-off of University of Auckland is developing peptide-based, self-adjuvanting NY-ESO-1 targeted &lt;b&gt;cancer&lt;/b&gt; vaccines, including SV-283, comprising a synthetic long peptide NY-ESO-1 antigen linked to a TLR2 agonist, for the potential treatment of solid cancers including melanoma, sarcoma, and ovarian, non-small cell lung &lt;b&gt;cancer&lt;/b&gt;, prostate, liver and breast cancers [ 1900909 ], [ 1900927 ], [ 1900949 ]. In June 2015, preclinical development was ongoing [ 1675028 ]. In July 2015, a trial of </Summary><CompaniesSecondary><Company>Auckland UniServices Ltd</Company><Company>University of Auckland</Company></CompaniesSecondary><ActionsSecondary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2015-08-01T00:00:00Z</AddedDate></Drug></SearchResults></drugResultsOutput>